(Q38109864)

29 August 2017

title

Evidence for the benefits of nonantipsychotic pharmacological augmentation in the treatment of depression (English)

1 reference

29 August 2017

Chia-Ming Chang

1

1 reference

29 August 2017

Soichiro Sato

series ordinal

2

1 reference

29 August 2017

Changsu Han

series ordinal

3

1 reference

29 August 2017

publication date

1 May 2013

1 reference

29 August 2017

1 reference

29 August 2017

volume

27 Suppl 1

1 reference

29 August 2017

page(s)

S21-7

1 reference

Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD.

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0030-1

Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0030-1

Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0030-1

Therapeutic options for treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0030-1

If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0030-1

Second-generation antipsychotics in major depressive disorder: update and clinical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0030-1

Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of clinicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0030-1

Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0030-1

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0030-1

An algorithm for the pharmacological treatment of depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0030-1

Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0030-1

Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0030-1

The benefit of lithium carbonate adjunct in refractory depression--fact or fiction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0030-1

Treatment of endogenous depressions resistant to tricyclic antidepressants or related drugs by lithium addition. Results of a placebo-controlled double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0030-1

Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0030-1

Lithium's emerging role in the treatment of refractory major depressive episodes: augmentation of antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0030-1

Lithium augmentation therapy in tricyclic-resistant depression. A controlled trial using lithium in low and normal doses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0030-1

Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0030-1

Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0030-1

Medication augmentation after the failure of SSRIs for depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0030-1

Patients With Severe Depression May Benefit From Buspirone Augmentation of Selective Serotonin Reuptake Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0030-1

Faster response in depressive patients treated with fluoxetine alone than in combination with buspirone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0030-1

Effectiveness of pindolol plus serotonin uptake inhibitors in depression: a meta-analysis of early and late outcomes from randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0030-1

A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0030-1

Methylphenidate extended release (OROS MPH) for the treatment of antidepressant-related sexual dysfunction in patients with treatment-resistant depression: results from a 4-week, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0030-1

Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0030-1

Meta-Analysis of the Effects of Eicosapentaenoic Acid (EPA) in Clinical Trials in Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0030-1

The role of folic acid in prevention and treatment of depression: an overview of existing evidence and implications for practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0030-1

Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0030-1

Systematic review of lamotrigine augmentation of treatment resistant unipolar depression (TRD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0030-1

Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0030-1

Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 1: predictors of clinical response in fluoxetine-resistant depression

21 January 2018

1 reference

12 December 2020

Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial.

1 reference

12 December 2020

A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids

1 reference

12 December 2020

A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants

1 reference

12 December 2020

Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study.

1 reference

12 December 2020

The pharmacologic management of SSRI-induced side effects: a survey of psychiatrists

1 reference

12 December 2020

Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study

1 reference

12 December 2020

STAR*D: revising conventional wisdom.

1 reference

12 December 2020

A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness.

1 reference

12 December 2020

Folic acid supplementation and prevention of birth defects

1 reference

12 December 2020

[STAR* D study: searching strategies regarding lack of response to an SSRI].

1 reference

12 December 2020

Lithium Augmentation of Nortriptyline for Subjects Resistant to Multiple Antidepressants

1 reference

12 December 2020

Possible augmentation of antidepressant response by buspirone

1 reference

12 December 2020

Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial

1 reference

12 December 2020

Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis

1 reference

12 December 2020

Adjunct low dose lithium carbonate in treatment-resistant depression: a placebo-controlled study.

1 reference

12 December 2020

Lithium carbonate augmentation of antidepressant treatment. An effective prescription for treatment-refractory depression

1 reference

12 December 2020

Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials.

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression

1 reference

12 December 2020

Prediction of treatment response in geriatric depression from baseline folate level: interaction with an SSRI or a tricyclic antidepressant

1 reference

12 December 2020

Lithium as an adjunct in the treatment of major depression.

1 reference

12 December 2020

Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association

1 reference

12 December 2020

A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation

1 reference

12 December 2020

Residual symptoms after partial remission: an important outcome in depression

1 reference

12 December 2020

A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression

1 reference

12 December 2020

Evaluating antidepressant therapies: remission as the optimal outcome

1 reference

12 December 2020

A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report

1 reference

12 December 2020

10.1007/S40263-012-0030-1

Identifiers

DOI

1 reference

29 August 2017

1 reference